glp 1 injections for weight loss phoenix Decoding GLP-1 Medications Medical Weight Loss & GLP-1

In 2014, the European Medicines Agency (EMA) approved afamelanotide (Scenesse) for the treatment of EPP, making it the first melanocortin receptor agonist to receive regulatory approval for a medical condition

There was a one-month increase of 18.6% in first-time AOM prescribing between December 2024 (when first-time AOMs accounted for 0.34% of all prescriptions) and January 2025 (when first-time AOMs accounted for 0.41% of all prescriptions)

Topical gels may be easier to use, but great care must be taken to avoid transferring testosterone to someone else though skin-to-skin contact

Patients may also experience some mild side effects, such as nausea, gastrointestinal symptoms like diarrhea or constipation, and headaches